TSC2 and lymphangioleiomyomatosis: With these LNPs for tuberous sclerosis 2 (Tsc2) mRNA delivery to the lungs, researchers successfully treated lymphangioleiomyomatosis, a monogenetic disorder induced by Tsc2 gene loss-of-function mutations.187